The Effects of Rosiglitazone Treatment on the Fibrinolytic System in Patients with Type 2 Diabetes Mellitus
| Autor: | Burhan Turgut, Sibel Guldiken, Ender Arikan, Armagan Tugrul, Muzaffer Demir, Özden Vural, Müjdat Kara, Jawed Fareed |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Waist 030204 cardiovascular system & hematology Tissue plasminogen activator Rosiglitazone 03 medical and health sciences 0302 clinical medicine Insulin resistance Internal medicine Plasminogen Activator Inhibitor 1 medicine Homeostasis Humans In patient business.industry Fibrinolysis Healthy subjects Type 2 Diabetes Mellitus Hematology General Medicine Middle Aged medicine.disease 030104 developmental biology Endocrinology Diabetes Mellitus Type 2 Tissue Plasminogen Activator Female Thiazolidinediones Insulin Resistance business Plasminogen activator medicine.drug |
| Zdroj: | Clinical and Applied Thrombosis/Hemostasis. 12:55-60 |
| ISSN: | 1938-2723 1076-0296 |
| DOI: | 10.1177/107602960601200109 |
| Popis: | Patients with type 2 diabetes mellitus (DM) are at risk for the development of cardiovascular diseases, which can in part be explained by disturbances in the hemostatic and fibrinolytic systems. The effects of rosiglitazone treatment on the fibrinolytic system and insulin sensitivity in patients with type 2 DM were assessed. Twenty-four patients with type 2 DM and 28 healthy subjects were enrolled in the study. Plasma global fibrinolytic capacity (GFC), tissue plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1) levels were measured. Insulin resistance was calculated by hoemostasis model assessment. Patients with type 2 DM then were placed on rosiglitazone (4 mg/day, for 12 weeks) in addition coexistent medication, and baseline tests were repeated. There was no difference between mean t-PA levels of the two groups. PAI-1 levels were higher in diabetic patients than control subjects (p < 0.01). Diabetic patients had lower GFC and t-PA/PAI-1 levels than control subjects (p < 0.05, p < 0.05). PAI-1 levels were positively correlated with waist circumference in diabetic group (r = 0.4, p < 0.05). After rosiglitazone treatment, there was no difference in mean plasma levels of GFC, t-PA, PAI-1 and t-PA/PAI-1 in diabetics. Insulin sensitivity significantly improved after the addition of rosiglitazone treatment in diabetic patients (p < 0.01). The short-term and low-dose treatment with rosiglitazone in type 2 diabetic patients has no effects on the fibrinolytic system, although it improves insulin sensitivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|